Sunday 30 August 2015
 
»
Tag
 
»
Boehringer Ingelheim

Boehringer Ingelheim introduces new treatment options for cancer

Boehringer Ingelheim, a leading pharmaceutical company, recently presented its new treatment for epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) at an educational session held in Dubai, UAE.

More…

Boehringer launches stroke management academy

Germany-based Boehringer Ingelheim, a leading pharmaceutical company, has launched an academy to establish comprehensive stroke management protocol in the region. The first of its kind introduced in the region, the Stroke Academy

More…

Hikma acquires assets of US pharma group

Hikma Pharmaceuticals, a leading medical group in the region, has signed an agreement with Boehringer Ingelheim Group of Companies to acquire the assets of Bedford Laboratories for $300 million. Hikma is a fast growing multination

More…

Boehringer plans production in Saudi Arabia

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, has entered into a tripartite agreement for local production in Saudi Arabia with Cigalah and Tabouk. The move came from Boehringer Ingelheim’s

More…

Boehringer plans production in Saudi Arabia

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, has entered into a tripartite agreement for local production in Saudi Arabia with Cigalah and Tabouk. The move came from Boehringer Ingelheim’s

More…

Boehringer Ingelheim posts 15pc growth in Mena

Boehringer Ingelheim, a research-driven pharmaceutical company, has achieved a growth of 14 per cent in the Mena region in the last fiscal year. Despite some challenges, the company succeeded in increasing its operating income and

More…

Boehringer, EFSD to fund diabetes research

A new programme unveiled by Boehringer Ingelheim, one of the world's leading pharmaceutical companies, and the European Foundation for the Study of Diabetes (EFSD) has invited European diabetes research projects to send in their applications

More…

Pfizer, BI inhaler may raise risk of death: study

A mist inhaler used to improve breathing in people with lung diseases including chronic bronchitis and emphysema may increase their risk of dying by 52 per cent, US and British researchers said. The increased risk occurred in patients who

More…

Linagliptin 'significantly lowers blood glucose'

Phase III studies of Linagliptin, a compound being investigated by Boehringer Ingelheim as a once-daily oral treatment in type 2 diabetes, showed that the drug significantly lowered blood glucose, a report said. The drug, a dipeptidyl pept

More…

Female sex pill flops with US advisers

A pink sex pill offered little help to women and came with unacceptable risks, US government advisers agreed on Friday, another setback in the search for a drug to boost female libido. German drugmaker Boehringer Ingelheim failed to convin

More…
 1 2 3 4 5 >  Last ›

calendarCalendar of Events

Ads